XML 38 R28.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaborative Arrangements (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Dec. 31, 2014
Information related to collaborative arrangements          
Less: amortization of capitalized fees paid to a related party $ (3,456) $ (3,456) $ (10,368) $ (10,368)  
Royalty revenue 48,422 33,088 147,034 89,294  
Strategic alliance - MABA program license 221 221 663 663  
Total net revenue 48,643 33,309 147,697 89,957  
GSK          
Information related to collaborative arrangements          
Total net revenue 48,643 33,309 $ 147,697 89,957  
LABA collaboration and Strategic Alliance agreements | GSK          
Information related to collaborative arrangements          
Percentage of economic interest in any future payments made under the agreements     15.00%    
Long-acting beta agonist (LABA) collaboration | GSK          
Information related to collaborative arrangements          
Royalties from a related party 51,878 36,544 $ 157,402 99,662  
Less: amortization of capitalized fees paid to a related party (3,456) (3,456) (10,368) (10,368)  
Royalty revenue 48,422 33,088 147,034 89,294  
Milestone fees paid         $ 220,000
Obligation for milestone payments 0   0    
Long-acting beta agonist (LABA) collaboration | GSK | RELVAR/BREO          
Information related to collaborative arrangements          
Royalties from a related party 44,604 31,917 $ 137,938 87,686  
Royalty rate for first level of annual global net sales (as a percent)     15.00%    
Annual global sales level used to determine royalty rate     $ 3,000,000    
Royalty rate for sales above first level of annual global net sales (as a percent)     5.00%    
Long-acting beta agonist (LABA) collaboration | GSK | ANORO          
Information related to collaborative arrangements          
Royalties from a related party 7,274 4,627 $ 19,464 11,976  
Long-acting beta agonist (LABA) collaboration | GSK | ANORO | Minimum          
Information related to collaborative arrangements          
Royalty rate for combination products (as a percent)     6.50%    
Long-acting beta agonist (LABA) collaboration | GSK | ANORO | Maximum          
Information related to collaborative arrangements          
Royalty rate for combination products (as a percent)     10.00%    
Strategic alliance - MABA program license | GSK          
Information related to collaborative arrangements          
Strategic alliance - MABA program license 221 $ 221 $ 663 $ 663  
Percentage of milestone payment     15.00%    
Strategic alliance - MABA program license | GSK | Maximum          
Information related to collaborative arrangements          
Potential future contingent payments receivable $ 363,000   $ 363,000